ANALYSIS OF THE IMMUNE RESPONSE IN VISCERAL LEISHMANIASIS

使用特定抗原的疫苗接种在利什曼病中未获成功 由于对免疫事件的了解不足，导致 疾病。我们正在寻找在小鼠模型中的最新发现 利什曼病将T辅助细胞分成两个亚群。 印度瓦拉纳西有一项研究人类骨骼的临床方案 在常规临床评估中获得的骨髓和脾抽吸物 内脏利什曼病患者。制备RNA，并 逆转录聚合酶链式反应半定量检测细胞因子转录产物 活动性疾病和治愈疾病的患者。来自疫苗行动的赠款 最近批准了一项计划，该计划将为美国的旅行提供资金。 调查人员和旅行、设备、用品和人员 印度网站。位于巴西维托利亚的该组织正在寻找潜在的 IL-12在外周血淋巴细胞免疫调节中的应用 在体外被刺激，看看抗原特异性免疫抑制 见于内脏疾病的患者可以逆转。初步数据 表明人类疾病在某些方面与老鼠模型相似。我们 会继续把这些地点发展为第三期的选址。 疫苗试验。

Vaccination using defined antigens has been unsuccessful in leishmaniasis due to an inadequate understanding of the immune events leading to disease. We are pursing recent findings in the mouse model of leishmaniasis which separate T helper cells into two sub-populations. A clinical protocol is in place in Varanasi, India, to study human bone marrow and splenic aspirates obtained during routine clinical evaluation of patients with visceral leishmaniasis. RNA is prepared and semi-quantitated using RT-PCR to determine the cytokine transcripts in patients with active and cured disease. A grant from the Vaccine Action Programme was recently approved that will fund travel for the U.S. investigators and travel, equipment, supplies, and personnel for the Indian site.The group in Vitoria, Brazil is looking at the potential for the use of IL-12 as an immunomodulator Lymphocytes from peripheral blood are stimulated in vitro to see if the antigen specific immunosuppression seen in patients with visceral disease can be reversed. Preliminary data indicates human disease parellels the mouse model in some respects. We will continue to develop these sites as potential places for phase III vaccine trials.